



COPY OF PAPERS
ORIGINALLY FILED

1636

Attorney Docket No. 5470.148CX2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Baldwin, et al.
Serial No.: 08/959,160
Filed: October 28, 1997
For: **USE OF NF- κ B INHIBITION IN COMBINATION THERAPY
FOR CANCER**

Group Art Unit: 1636

33/D
Huta
3/12/03

February 13, 2003

Commissioner for Patents
Washington, DC 20231

RESPONSE TO OFFICIAL ACTION

In the claims:

Please cancel claims 4 and 9-10, without prejudice or disclaimer

Remarks


Dear Sir:

In response to the Official Action dated January 13, 2003, Applicant hereby
objects the species doxorubicin. All pending claims are currently readable thereon.

Claims 4 and 9-10 have been cancelled above, consistent with the helpful

suggestions provided by the Examiner on page 4 of the Official Action.

Respectfully submitted,


Kenneth D. Sibley
Registration No. 31,665




20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on February 13, 2003.



Vickie Diane Prior

Date of Signature: February 13, 2003

Doc. No. 292926

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900